Sun, Dec 21, 2014, 5:11 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Novogen Limited Message Board

  • moosefromoz moosefromoz Feb 19, 2013 8:38 PM Flag

    Technology not just in the oncology field?

    5 February 2013
    ASX RELEASE
    Novogen Announces Filing of Key Patent Application
    Novogen is pleased to announce the filing of a provisional patent application
    covering the novel technology associated with the manufacture and use of it new
    class of molecules referred to as `super-benzopyrans’.
    The invention is based on technology that Novogen acquired when it purchased
    Triaxial Pharmaceuticals Pty Ltd on 7 Dec 2012. Triaxial had developed a novel
    manufacturing process that involved chemically `bending’ molecules to allow the
    insertion of atoms not previously possible. The Triaxial goal was the ability to
    design and build molecules to suit particular therapeutic applications. The initial
    result of this technology was the creation of an entirely new family of
    compounds known as super-benzopyrans, hitherto impossible to manufacture
    by existing techniques, and displaying a range of anti-cancer functions not
    previously experienced.
    In the 2 months since the merger, Novogen has been conducting a series of
    manufacturing studies designed to strengthen its patent position through
    `reduction to practice’, a key requirement for sound patent protection. These
    studies have focused on the Company’s inaugural drug candidate, CS-6, with the
    manufacturing process now in place and able to produce the quantities of drug
    required for its developmental program.
    Provisional patent application No 2012905600 covers the three cornerstones of
    patent protection around Novogen’s initial family of super-benzopyrans: method
    of manufacture, method of use, and composition of matter.
    Dr Andrew Heaton, Novogen Chief Scientist, said, ” the design and manufacturing
    technology that is the basis of the Novogen technology, in our view heralds a new
    era in drug discovery, and not just in the oncology field.”
    He added, “the ability to create a potent anti-cancer drug such as CS-6, and to
    then add a further layer of design to improve its ability to attack cancer cells, and
    then to add a further design layer to increase the likelihood of it being able to
    cross the blood-brain barrier, is a practical example of what is achievable with
    this technology.”
    Professor Graham Kelly, Novogen CEO, said, “lodging this patent application
    marks two milestones. The first is our overriding efforts to protect our valuable
    intellectual property. The second is that we have achieved the means to
    manufacture CS-6 economically and efficiently, something that is essential to our
    objective of taking CS-6 into humans with primary brain cancer in 2014.

 
NVGN
2.58-0.1500(-5.49%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.